Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

About this update from Pulse Biosciences, Inc

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/950c1a2783942602ab32f73b6f841ad8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o3EOh3r89JH6LFiiDvXiPw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/950c1a2783942602ab32f73b6f841ad8","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Wudc3dQFk_gIWN0lFihrvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/950c1a2783942602ab32f73b6f841ad8","width":1024,"height":512}},"lazy":false},{"type":"text","content":"HAYWARD, Calif., February 19, 2026--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025.","length":338,"tagName":"p"},{"type":"text","content":"Recent Business Highlights","length":26,"tagName":"p"},{"type":"text","content":"Endocardial Catheter AF Ablation","length":32,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Highlighted 100% procedural success, or freedom from atrial fibrillation (AF), at 6 months and 96% procedural success at one year, of evaluable patients, following treatments with the nPulse Cardiac Catheter System in the first-in-human feasibility study which was presented as late-breaking data at the 31st Annual AF Symposium Meeting.","length":337,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Received FDA approval to commence a pivotal IDE study for the treatment of paroxysmal atrial fibrillation with the nPulse Cardiac Catheter System in Q4 2025. The first patient is expected to be enrolled in the next few months and the last patient is expected to be enrolled in Q4 2026.","length":285,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":622,"olType":false},{"type":"text","content":"Surgical AF Ablation","length":20,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Continued enrollment in the nPulse Cardiac Surgery System IDE pivotal study, NANOCLAMP A...

More updates from Pulse Biosciences, Inc